Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

  • End date
    May 21, 2027
  • participants needed
  • sponsor
    Fudan University
Updated on 25 February 2022


Adjuvant chemotherapy has been widely adopted worldwide for locally advanced colon cancer. However, more and more studies have found better efficacy and potential advantages of perioperative or neoadjuvant chemotherapy. The sooner the systemic chemotherapy is received, the better suppression it has on activity of tumor growth factors. Pre-operative chemotherapy may eliminate tiny metastases. It may also shrink the invasion of tumor before surgery, and thus reducing operational trauma and expediting recovery. With advances in radiology and tomography, staging before surgery is accurate enough to identify risks and prognosis for patients. The phase II trial conducted by our department has yielded encouraging results (N=47, CapeOX regimen, NCT02415829): after the neoadjuvant chemotherapy, no subject had disease progression, 68.1% subjects reached complete or partial response. Besides, the toxicity of neoadjuvant CapeOX chemotherapy was acceptable. The present randomized controlled phase III trial will be conducted to further compare efficacy and safety of the neoadjuvant and adjuvant CapeOX chemotherapy for patients with locally advanced resectable colon cancer in China. This study may have two periods, each will last for approximately 5 years. After the first period (n=994), if the results of the test group are better than the control group, the study will be terminated. Otherwise, the study will enter into period 2 (n=376) through selecting out genetically sensitive subjects and repeating the same trial process as period 1.

Condition Locally Advanced Colon Cancer
Treatment capecitabine plus oxaliplatin before and after surgery, capecitabine plus oxaliplatin after surgery
Clinical Study IdentifierNCT03125980
SponsorFudan University
Last Modified on25 February 2022


Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2
Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count1.5109/L, Platelet count100109/L, Hemoglobin80g/L, Serum bilirubin24umol/L, Alanine aminotransferase and aspartate aminotransferase 60IU/L, Serum creatinine110 umol/L
No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception
Be in a condition to receive a surgery/procedure
No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer
No previous systemic chemotherapy for treating colon cancer
No other chemotherapy at the same time
Expected lifetime longer than three months
Be willing and able to understand the study and to provide written informed consent

Exclusion Criteria

End-stage cachexia patients
Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy
Metastatic carcinoma
Moderate or above anemia caused by serious local tumor bleeding
Incomplete or complete intestinal obstruction
Known to be allergic to oxaliplatin or capecitabine
Active hepatitis, severe coagulation disorder patients
Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures
Known to have deficient dihydropyrimidine dehydrogenase (DPD)
Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric historysevere infection; active disseminated intravascular coagulation
Unable or unwilling to abide by the study plan
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note